Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287963 · ClinicalTrials.gov registry record · Phase 1
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00287963 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 18 participants.
The verdict
NCT00287963, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as topotecan and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of topotecan when given together with vinorelbine in treating patients with recurrent lung cancer.
Interventions
- DRUG topotecan hydrochloride
- DRUG vinorelbine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287963
The ClinicalTrials.gov registry entry for NCT00287963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which topotecan hydrochloride is the first listed.
NCT00287963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287963 about?
NCT00287963 is a clinical study titled "Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as topotecan and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I tr...
What is the current status of trial NCT00287963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2004-02. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00287963?
The interventions under investigation include: topotecan hydrochloride (DRUG), vinorelbine tartrate (DRUG).
Who is sponsoring clinical trial NCT00287963?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.